APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Proprotein Convertase Subtilisin & Kexin Type 9

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Analysis and Forecast 2026-2032

19 December 2025191 pages

Choose your research edition.

Industry ResearchProprotein Convertase Subtilisin & Kexin Type 9 Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Proprotein Convertase Subtilisin & Kexin Type 9 Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Proprotein Convertase Subtilisin & Kexin Type 9 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Proprotein Convertase Subtilisin & Kexin Type 9 Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Proprotein Convertase Subtilisin & Kexin Type 9 Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Proprotein Convertase Subtilisin & Kexin Type 9 market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Proprotein Convertase Subtilisin & Kexin Type 9 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Proprotein Convertase Subtilisin & Kexin Type 9 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Proprotein Convertase Subtilisin & Kexin Type 9 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Proprotein Convertase Subtilisin & Kexin Type 9 is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Proprotein Convertase Subtilisin & Kexin Type 9 include Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, Novartis AG, Eli Lilly and Co, Pfizer Inc, The Medicines Company, Serometrix LLC, Regeneron Pharmaceuticals Inc, Kowa Co Ltd and Ensemble Therapeutics Corp, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Proprotein Convertase Subtilisin & Kexin Type 9, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Proprotein Convertase Subtilisin & Kexin Type 9, also provides the revenue of main regions and countries. Of the upcoming market potential for Proprotein Convertase Subtilisin & Kexin Type 9, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Proprotein Convertase Subtilisin & Kexin Type 9 revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Proprotein Convertase Subtilisin & Kexin Type 9 market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Proprotein Convertase Subtilisin & Kexin Type 9 revenue, projected growth trends, production technology, application and end-user industry.

Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Company

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd

Novartis AG

Eli Lilly and Co

Pfizer Inc

The Medicines Company

Serometrix LLC

Regeneron Pharmaceuticals Inc

Kowa Co Ltd

Ensemble Therapeutics Corp

Dicerna Pharmaceuticals Inc

Catabasis Pharmaceuticals Inc

BioLingus AG

Bioleaders Corp

Betagenon AB

AFFiRiS AG

Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Type

SX-PCK9

O-304

K-312

DCRPCSK-9

BLSM-201

Others

Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Application

Cardiovascular Disease

Homozugous Familial Hyperchalesterolemia

Liver Disease

Metabolic Syndrome

Others

Proprotein Convertase Subtilisin & Kexin Type 9 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Proprotein Convertase Subtilisin & Kexin Type 9 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Proprotein Convertase Subtilisin & Kexin Type 9 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Proprotein Convertase Subtilisin & Kexin Type 9.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Proprotein Convertase Subtilisin & Kexin Type 9 in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Proprotein Convertase Subtilisin & Kexin Type 9 company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Proprotein Convertase Subtilisin & Kexin Type 9 revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. SX-PCK9 Major Player Table 3. O-304 Major Player Table 4. K-312 Major Player Table 5. DCRPCSK-9 Major Player Table 6. BLSM-201 Major Player Table 7. Others Major Player Table 8. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Cardiovascular Disease Major Player Table 10. Homozugous Familial Hyperchalesterolemia Major Player Table 11. Liver Disease Major Player Table 12. Metabolic Syndrome Major Player Table 13. Others Major Player Table 14. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Trends Table 15. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Drivers Table 16. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Opportunities and Challenges Table 17. Proprotein Convertase Subtilisin & Kexin Type 9 Industry Restraints Table 18. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 19. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (2021-2026) & (US$ Million) Table 20. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Region (2021-2026) Table 21. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (2027-2032) & (US$ Million) Table 22. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Region (2027-2032) Table 23. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Players (US$ Million) & (2021-2026) Table 24. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Players (2021-2026) Table 25. Global Proprotein Convertase Subtilisin & Kexin Type 9 Key Players Ranking, 2024 VS 2025 VS 2026 Table 26. Global Proprotein Convertase Subtilisin & Kexin Type 9 Key Players Headquarters & Area Served Table 27. Global Proprotein Convertase Subtilisin & Kexin Type 9 Players, Product Type & Application Table 28. Global Proprotein Convertase Subtilisin & Kexin Type 9 Players Establishment Date Table 29. Global Players Market Concentration Ratio (CR5 and HHI) Table 30. Global Proprotein Convertase Subtilisin & Kexin Type 9 by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 31. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026) & (US$ Million) Table 33. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032) & (US$ Million) Table 34. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Type (2021-2026) Table 35. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Type (2027-2032) Table 36. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026) & (US$ Million) Table 38. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032) & (US$ Million) Table 39. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Application (2021-2026) Table 40. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Application (2027-2032) Table 41. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Information Table 42. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview Table 43. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 45. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Development Table 46. Novartis AG Company Information Table 47. Novartis AG Business Overview Table 48. Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 50. Novartis AG Recent Development Table 51. Eli Lilly and Co Company Information Table 52. Eli Lilly and Co Business Overview Table 53. Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 55. Eli Lilly and Co Recent Development Table 56. Pfizer Inc Company Information Table 57. Pfizer Inc Business Overview Table 58. Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 60. Pfizer Inc Recent Development Table 61. The Medicines Company Company Information Table 62. The Medicines Company Business Overview Table 63. The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 65. The Medicines Company Recent Development Table 66. Serometrix LLC Company Information Table 67. Serometrix LLC Business Overview Table 68. Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 70. Serometrix LLC Recent Development Table 71. Regeneron Pharmaceuticals Inc Company Information Table 72. Regeneron Pharmaceuticals Inc Business Overview Table 73. Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 75. Regeneron Pharmaceuticals Inc Recent Development Table 76. Kowa Co Ltd Company Information Table 77. Kowa Co Ltd Business Overview Table 78. Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 80. Kowa Co Ltd Recent Development Table 81. Ensemble Therapeutics Corp Company Information Table 82. Ensemble Therapeutics Corp Business Overview Table 83. Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 85. Ensemble Therapeutics Corp Recent Development Table 86. Dicerna Pharmaceuticals Inc Company Information Table 87. Dicerna Pharmaceuticals Inc Business Overview Table 88. Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 90. Dicerna Pharmaceuticals Inc Recent Development Table 91. Catabasis Pharmaceuticals Inc Company Information Table 92. Catabasis Pharmaceuticals Inc Business Overview Table 93. Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 95. Catabasis Pharmaceuticals Inc Recent Development Table 96. BioLingus AG Company Information Table 97. BioLingus AG Business Overview Table 98. BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 100. BioLingus AG Recent Development Table 101. Bioleaders Corp Company Information Table 102. Bioleaders Corp Business Overview Table 103. Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 105. Bioleaders Corp Recent Development Table 106. Betagenon AB Company Information Table 107. Betagenon AB Business Overview Table 108. Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 110. Betagenon AB Recent Development Table 111. AFFiRiS AG Company Information Table 112. AFFiRiS AG Business Overview Table 113. AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio Table 115. AFFiRiS AG Recent Development Table 116. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026) & (US$ Million) Table 117. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032) & (US$ Million) Table 118. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026) & (US$ Million) Table 119. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032) & (US$ Million) Table 120. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021-2026) & (US$ Million) Table 122. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (US$ Million) & (2027-2032) Table 123. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026) & (US$ Million) Table 124. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032) & (US$ Million) Table 125. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026) & (US$ Million) Table 126. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032) & (US$ Million) Table 127. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021-2026) & (US$ Million) Table 129. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (US$ Million) & (2027-2032) Table 130. China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026) & (US$ Million) Table 131. China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032) & (US$ Million) Table 132. China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026) & (US$ Million) Table 133. China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032) & (US$ Million) Table 134. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026) & (US$ Million) Table 135. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032) & (US$ Million) Table 136. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026) & (US$ Million) Table 137. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032) & (US$ Million) Table 138. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 139. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Region (US$ Million) & (2021-2026) Table 140. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Region (US$ Million) & (2027-2032) Table 141. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026) & (US$ Million) Table 142. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032) & (US$ Million) Table 143. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026) & (US$ Million) Table 144. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032) & (US$ Million) Table 145. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 146. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021-2026) & (US$ Million) Table 147. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (US$ Million) & (2027-2032) Table 148. Research Programs/Design for This Report Table 149. Authors List of This Report Table 150. Secondary Sources Table 151. Primary Sources List of Figures Figure 1. Proprotein Convertase Subtilisin & Kexin Type 9 Image Figure 2. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Share 2021 VS 2025 VS 2032 Figure 4. SX-PCK9 Image Figure 5. O-304 Image Figure 6. K-312 Image Figure 7. DCRPCSK-9 Image Figure 8. BLSM-201 Image Figure 9. Others Image Figure 10. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size Share 2021 VS 2025 VS 2032 Figure 12. Cardiovascular Disease Image Figure 13. Homozugous Familial Hyperchalesterolemia Image Figure 14. Liver Disease Image Figure 15. Metabolic Syndrome Image Figure 16. Others Image Figure 17. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size (US$ Million) & (2021-2032) Figure 18. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 19. Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Share by Region: 2021 VS 2025 VS 2032 Figure 20. Global Proprotein Convertase Subtilisin & Kexin Type 9 Players Revenue Share Top 10 and Top 5 in 2025 Figure 21. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Type (2021-2032) Figure 25. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 26. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 27. Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Application (2021-2032) Figure 28. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Type (2021-2032) Figure 30. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Application (2021-2032) Figure 31. North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Country (2021-2032) Figure 32. United States Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Canada Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. Mexico Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 36. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Type (2021-2032) Figure 37. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Application (2021-2032) Figure 38. Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Country (2021-2032) Figure 39. Germany Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. France Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. U.K. Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Italy Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Spain Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Russia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. Netherlands Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 46. Nordic Countries Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 47. China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Type (2021-2032) Figure 49. China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Application (2021-2032) Figure 50. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 51. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Type (2021-2032) Figure 52. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Application (2021-2032) Figure 53. Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Region (2021-2032) Figure 54. Japan Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. South Korea Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. India Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Australia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Taiwan Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Southeast Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (2021-2032) & (US$ Million) Figure 61. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Type (2021-2032) Figure 62. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Application (2021-2032) Figure 63. SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Country (2021-2032) Figure 64. Brazil Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Argentina Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Chile Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Colombia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Peru Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Saudi Arabia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Israel Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. UAE Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Turkey Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Iran Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 74. Egypt Proprotein Convertase Subtilisin & Kexin Type 9 Revenue YoY Growth (US$ Million) & (2021-2032) Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • SX-PCK9
  • O-304
  • K-312
  • DCRPCSK-9
  • BLSM-201
  • Others
Applications
  • Cardiovascular Disease
  • Homozugous Familial Hyperchalesterolemia
  • Liver Disease
  • Metabolic Syndrome
  • Others
Companies covered
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Novartis AG
  • Eli Lilly and Co
  • Pfizer Inc
  • The Medicines Company
  • Serometrix LLC
  • Regeneron Pharmaceuticals Inc
  • Kowa Co Ltd
  • Ensemble Therapeutics Corp
  • Dicerna Pharmaceuticals Inc
  • Catabasis Pharmaceuticals Inc
  • BioLingus AG
  • Bioleaders Corp
  • Betagenon AB
  • AFFiRiS AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Proprotein Convertase Subtilisin & Kexin Type 9 Market by Type
  3. 1.2.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 SX-PCK9
  5. 1.2.3 O-304
  6. 1.2.4 K-312
  7. 1.2.5 DCRPCSK-9
  8. 1.2.6 BLSM-201
  9. 1.2.7 Others
  10. 1.3 Proprotein Convertase Subtilisin & Kexin Type 9 Market by Application
  11. 1.3.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Cardiovascular Disease
  13. 1.3.3 Homozugous Familial Hyperchalesterolemia
  14. 1.3.4 Liver Disease
  15. 1.3.5 Metabolic Syndrome
  16. 1.3.6 Others
  17. 1.4 Assumptions and Limitations
  18. 1.5 Study Goals and Objectives
2 Proprotein Convertase Subtilisin & Kexin Type 9 Market Dynamics
  1. 2.1 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Trends
  2. 2.2 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Drivers
  3. 2.3 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Opportunities and Challenges
  4. 2.4 Proprotein Convertase Subtilisin & Kexin Type 9 Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Perspective (2021-2032)
  2. 3.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Growth Trends by Region
  3. 3.2.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (2021-2026)
  5. 3.2.3 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Players
  2. 4.1.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Players (2021-2026)
  3. 4.1.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Proprotein Convertase Subtilisin & Kexin Type 9 Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Proprotein Convertase Subtilisin & Kexin Type 9 Key Players Headquarters & Area Served
  7. 4.4 Global Proprotein Convertase Subtilisin & Kexin Type 9 Players, Product Type & Application
  8. 4.5 Global Proprotein Convertase Subtilisin & Kexin Type 9 Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Market CR5 and HHI
  11. 4.6.3 2025 Proprotein Convertase Subtilisin & Kexin Type 9 Tier 1, Tier 2, and Tier 3
5 Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Type
  1. 5.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2032)
  3. 5.3 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Type (2021-2032)
6 Proprotein Convertase Subtilisin & Kexin Type 9 Market Size by Application
  1. 6.1 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2032)
  3. 6.3 Global Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  2. 7.1.1 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Information
  3. 7.1.2 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Business Overview
  4. 7.1.3 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  6. 7.1.5 Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Recent Developments
  7. 7.2 Novartis AG
  8. 7.2.1 Novartis AG Company Information
  9. 7.2.2 Novartis AG Business Overview
  10. 7.2.3 Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  12. 7.2.5 Novartis AG Recent Developments
  13. 7.3 Eli Lilly and Co
  14. 7.3.1 Eli Lilly and Co Company Information
  15. 7.3.2 Eli Lilly and Co Business Overview
  16. 7.3.3 Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lilly and Co Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  18. 7.3.5 Eli Lilly and Co Recent Developments
  19. 7.4 Pfizer Inc
  20. 7.4.1 Pfizer Inc Company Information
  21. 7.4.2 Pfizer Inc Business Overview
  22. 7.4.3 Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  24. 7.4.5 Pfizer Inc Recent Developments
  25. 7.5 The Medicines Company
  26. 7.5.1 The Medicines Company Company Information
  27. 7.5.2 The Medicines Company Business Overview
  28. 7.5.3 The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  29. 7.5.4 The Medicines Company Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  30. 7.5.5 The Medicines Company Recent Developments
  31. 7.6 Serometrix LLC
  32. 7.6.1 Serometrix LLC Company Information
  33. 7.6.2 Serometrix LLC Business Overview
  34. 7.6.3 Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Serometrix LLC Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  36. 7.6.5 Serometrix LLC Recent Developments
  37. 7.7 Regeneron Pharmaceuticals Inc
  38. 7.7.1 Regeneron Pharmaceuticals Inc Company Information
  39. 7.7.2 Regeneron Pharmaceuticals Inc Business Overview
  40. 7.7.3 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Regeneron Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  42. 7.7.5 Regeneron Pharmaceuticals Inc Recent Developments
  43. 7.8 Kowa Co Ltd
  44. 7.8.1 Kowa Co Ltd Company Information
  45. 7.8.2 Kowa Co Ltd Business Overview
  46. 7.8.3 Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Kowa Co Ltd Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  48. 7.8.5 Kowa Co Ltd Recent Developments
  49. 7.9 Ensemble Therapeutics Corp
  50. 7.9.1 Ensemble Therapeutics Corp Company Information
  51. 7.9.2 Ensemble Therapeutics Corp Business Overview
  52. 7.9.3 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Ensemble Therapeutics Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  54. 7.9.5 Ensemble Therapeutics Corp Recent Developments
  55. 7.10 Dicerna Pharmaceuticals Inc
  56. 7.10.1 Dicerna Pharmaceuticals Inc Company Information
  57. 7.10.2 Dicerna Pharmaceuticals Inc Business Overview
  58. 7.10.3 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Dicerna Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  60. 7.10.5 Dicerna Pharmaceuticals Inc Recent Developments
  61. 7.11 Catabasis Pharmaceuticals Inc
  62. 7.11.1 Catabasis Pharmaceuticals Inc Company Information
  63. 7.11.2 Catabasis Pharmaceuticals Inc Business Overview
  64. 7.11.3 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Catabasis Pharmaceuticals Inc Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  66. 7.11.5 Catabasis Pharmaceuticals Inc Recent Developments
  67. 7.12 BioLingus AG
  68. 7.12.1 BioLingus AG Company Information
  69. 7.12.2 BioLingus AG Business Overview
  70. 7.12.3 BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  71. 7.12.4 BioLingus AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  72. 7.12.5 BioLingus AG Recent Developments
  73. 7.13 Bioleaders Corp
  74. 7.13.1 Bioleaders Corp Company Information
  75. 7.13.2 Bioleaders Corp Business Overview
  76. 7.13.3 Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Bioleaders Corp Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  78. 7.13.5 Bioleaders Corp Recent Developments
  79. 7.14 Betagenon AB
  80. 7.14.1 Betagenon AB Company Information
  81. 7.14.2 Betagenon AB Business Overview
  82. 7.14.3 Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Betagenon AB Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  84. 7.14.5 Betagenon AB Recent Developments
  85. 7.15 AFFiRiS AG
  86. 7.15.1 AFFiRiS AG Company Information
  87. 7.15.2 AFFiRiS AG Business Overview
  88. 7.15.3 AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Revenue and Gross Margin (2021-2026)
  89. 7.15.4 AFFiRiS AG Proprotein Convertase Subtilisin & Kexin Type 9 Product Portfolio
  90. 7.15.5 AFFiRiS AG Recent Developments
8 North America
  1. 8.1 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (2021-2032)
  2. 8.2 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2032)
  3. 8.2.1 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026)
  4. 8.2.2 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032)
  5. 8.3 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Type (2021-2032)
  6. 8.4 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2032)
  7. 8.4.1 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026)
  8. 8.4.2 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032)
  9. 8.5 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Application (2021-2032)
  10. 8.6 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country
  11. 8.6.1 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021-2026)
  13. 8.6.3 North America Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (2021-2032)
  2. 9.2 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2032)
  3. 9.2.1 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026)
  4. 9.2.2 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032)
  5. 9.3 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Type (2021-2032)
  6. 9.4 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2032)
  7. 9.4.1 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026)
  8. 9.4.2 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032)
  9. 9.5 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Application (2021-2032)
  10. 9.6 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country
  11. 9.6.1 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021-2026)
  13. 9.6.3 Europe Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (2021-2032)
  2. 10.2 China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2032)
  3. 10.2.1 China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026)
  4. 10.2.2 China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032)
  5. 10.3 China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Type (2021-2032)
  6. 10.4 China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2032)
  7. 10.4.1 China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026)
  8. 10.4.2 China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032)
  9. 10.5 China Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (2021-2032)
  2. 11.2 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2032)
  3. 11.2.1 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026)
  4. 11.2.2 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032)
  5. 11.3 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Type (2021-2032)
  6. 11.4 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2032)
  7. 11.4.1 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026)
  8. 11.4.2 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032)
  9. 11.5 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Application (2021-2032)
  10. 11.6 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country
  11. 11.6.1 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021-2026)
  13. 11.6.3 Asia Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue (2021-2032)
  2. 12.2 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Type (2027-2032)
  5. 12.3 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Application (2027-2032)
  9. 12.5 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country
  11. 12.6.1 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Proprotein Convertase Subtilisin & Kexin Type 9 Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst